TCM
LXRX icon

Tekla Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Tekla Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-353,900
Closed -$3.8M – 148
2015
Q3 		$3.8M Buy
+353,900
New +$3.87M 0.14% 111

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tekla Capital Management's LXRX Position: Q1 2019 in Review

Tekla Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2019, closing a stake of 70,000 shares — an estimated $465K sold.

Tekla Capital Management first reported a position in LXRX in Q3 2015 and held it in 7 quarters. The position peaked at $3.8M in Q3 2015. 121 funds tracked by Wall St. Rank hold LXRX as of Q1 2019.

  • Tekla Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Tekla Capital Management sold 70,000 Lexicon Pharmaceuticals shares in Q1 2019, an estimated $465K.
  • Tekla Capital Management first reported a position in Lexicon Pharmaceuticals in Q3 2015 and held it in 7 quarters.
  • Tekla Capital Management's Lexicon Pharmaceuticals position peaked at $3.8M in Q3 2015.
  • 121 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2019.

Based on Tekla Capital Management's 13F filing for Q1 2019, filed 14 May 2019.